Cytori Therapeutics, Inc.

Cytori Therapeutics, Inc.
3020 Callan Road
San Diego, CA 92121
United States - Map
Phone: 858-458-0900
Fax: 858-458-0994
Web Site: http://www.cytoritx.com
Cytori Therapeutics, Inc. engages in the development, manufacture, and sale of medical technologies to enable the practice of regenerative medicine. The company develops its product pipeline for the treatments of cardiovascular disease, spinal disc degeneration, gastrointestinal disorders, liver and renal disease, and pelvic health conditions. Its principal products include the Celution System family of products, which processes patients' cells at the bedside in real time. Each member of the Celution System family of products consists of a central device, a related single-use consumable used for each patient procedure, proprietary enzymes, and related instrumentation. The company also offers Celution 800/CRS System for the European cosmetic and reconstructive surgery market through a network of medical distributors; and the Celution 900/MB in Japan through its commercialization partner as part of the StemSource Cell Bank, which prepares cells for cryopreservation. Cytori Therapeutics is conducting two clinical trials on adipose-derived stem and regenerative cells processed with the Celution 600 System in patients suffering from chronic myocardial ischemia and in heart attack patients. In addition, it develops and sells thin film bioresorbable implants in Japan. Further, the company operates a tissue bank facility for the preservation of stem and regenerative cells extracted from adipose tissue. Additionally, it has a joint venture with Olympus Corporation to develop and manufacture second generation devices based on its Celution system. The company was founded in 1996 and is headquartered in San Diego, California


DiggDigg   | RedditReddit   | Add to Mixx!MixxDeldel.icio.usStumble Stumble it!Bookmark and Share Share it


More articles Cell Therapeutics, Inc

More articles Stem Cell Companies

More articles Stem Cell Stocks

More articles BioMimetic Therapeutics (BMTI)

More articles Pluristem Therapeutics-PTSI

More articles Osiris Therapeutics-OSIR

More articles Cytori Therapeutics, Inc.

More articles ThermoGenesis (KOOL)

More articles Nutra Pharma (OTCBB:NPHC)

More articles Human Embryonic Stem Cell Market

More articles RTI Biologics (RTIX)

More articles Aastrom Biosciences -ASTM



XOMA 052 Designated Orphan Drug by FDA ...
Published:Wed, 04 Aug 2010 05:00:00 -0700
BERKELEY, Calif. -- XOMA Ltd. , a leader in the discovery and development of therapeutic antibodies, announced that the U.S. Food and Drug Administration has designated XOMA 052, ......
XOMA to Announce 2010 Second Quarter Fi...
Published:Mon, 02 Aug 2010 05:00:00 -0700
BERKELEY, Calif. -- XOMA Ltd. , a leader in the discovery and development of antibody therapeutics, announced that the company will host a webcast conference call on Monday, Augus......
XOMA 052 Orphan Drug Designation for Be...
Published:Thu, 29 Jul 2010 05:00:00 -0700
BERKELEY, Calif. -- XOMA Ltd. , a leader in the discovery and development of therapeutic antibodies, announced that the Committee for Orphan Medical Products of the European Medic......
Biotech Stocks: Depomed, Dendreon lead ...
Published:Wed, 04 Aug 2010 07:55:59 -0700
Depomed lead gains among drug stocks a day after it said Pfizer will not file a patent infringement lawsuit to prevent the launch of a painkiller.......
Trader Favorite Dendreon Spikes On Prov...
Published:Wed, 04 Aug 2010 08:00:00 -0700
After soaring higher on the FDA approval of its Provenge prostate cancer vaccine in April, volatile Dendreon quickly retreated to well below its pre-approval pricing, but sales fi......
© 2010 | Privacy Policy | Powered By Noomle.com | SiteMap